PRU
59
5
UPS
41
-4
TSCO
53
-5
ICE
62
3
MSFT
51
-4
CMA
67
3
AFL
49
3
BAX
35
-3
NEM
38
-4
STX
55
-5
ADBE
49
3
HON
70
5
CHD
50
2
CAT
64
2
JNJ
39
-2
COF
68
3
INTU
63
3
MU
42
-4
OI
49
6
BLK
75
3
PRU
59
5
UPS
41
-4
TSCO
53
-5
ICE
62
3
MSFT
51
-4
CMA
67
3
AFL
49
3
BAX
35
-3
NEM
38
-4
STX
55
-5
ADBE
49
3
HON
70
5
CHD
50
2
CAT
64
2
JNJ
39
-2
COF
68
3
INTU
63
3
MU
42
-4
OI
49
6
BLK
75
3
Financhill
Back

Keros Therapeutics 10K Form

Buy
80

KROS
Keros Therapeutics

Last Price:
64.84
Seasonality Move:
23.73%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KROS News And Ratings

See the #1 stock for the next 7 days that we like better than KROS

KROS Financial Statistics

Sales & Book Value

Annual Sales: $151K
Cash Flow: $-30.89M
Price / Cash Flow: 0
Annual Sales: $13.57
Price / Book: 5.18

Profitability

EPS (TTM): -5.21000
Net Income (TTM): $-181.57M
Gross Margin: --
Return on Equity: -44.6%
Return on Assets: -40.96%

Keros Therapeutics Earnings Forecast

Key Keros Therapeutics Financial Ratios

  • The Research & Development expenses have been 89,574.83% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of KROS is -101,319.21% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 1 years.

Keros Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KROS
CUSIP: 492327
Website: kerostx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 19.03
Quick Ratio: 18.36

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KROS Technical Analysis vs Fundamental Analysis

Buy
80
Keros Therapeutics (KROS) is a Buy

Is Keros Therapeutics a Buy or a Sell?